D B Hunninghake
About
In The Last Decade
D B Hunninghake
30 papers receiving 1.0k citations
Hit Papers
Peers
Comparison fields: 5 of 98
- Surgery 669
- Endocrinology, Diabetes and Metabolism 375
- Cardiology and Cardiovascular Medicine 199
- Economics and Econometrics 174
- Molecular Biology 135
Countries citing papers authored by D B Hunninghake
This map shows the geographic impact of D B Hunninghake's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D B Hunninghake with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D B Hunninghake more than expected).
Fields of papers citing papers by D B Hunninghake
This network shows the impact of papers produced by D B Hunninghake. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D B Hunninghake. The network helps show where D B Hunninghake may publish in the future.
Co-authorship network of co-authors of D B Hunninghake
This figure shows the co-authorship network connecting the top 25 collaborators of D B Hunninghake. A scholar is included among the top collaborators of D B Hunninghake based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D B Hunninghake. D B Hunninghake is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 87 | |
| 2 | 12 | |
| 3 | 28 | |
| 4 | 3 | |
| 5 | 68 | |
| 6 | 1 | |
| 7 | Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. | 62 |
| 8 | 16 | |
| 9 | 9 | |
| 10 | 47 | |
| 11 | 2 | |
| 12 | 1 | |
| 13 | 8 | |
| 14 | Therapeutic response to lovasatain (Mevinolin) in nonfamilial hypercholesterolemia - A Multicenter study | 159 |
| 15 | Effect of time of administration of cholestyramine on plasma lipids and lipoproteins. | 5 |
| 16 | Recruitment from Clinical Trials: The Lipid Research Clinics' Coronary Primary Prevention Trial Experience and Its Implication for Future Trials | 2 |
| 17 | The effect of cholestyramine and colestipol on the absorption of hydrochlorothiazide. | 22 |
| 18 | Alterations of plasma high-density lipoprotein cholesterol levels associated with consumption of selected medications. The Lipid Research Clinics Program Prevalence Study. | 33 |
| 19 | 4 | |
| 20 | 12 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.